Hospital
Ahmc San Gabriel Valley Medical
Ahmc San Gabriel Valley Medical was paid $6.96M by Medicaid between Jan 2018 and Dec 2024, across 140 billing codes. Its largest line is 0450, Emergency room services — 21% of everything it billed.
33Billing provider infoAHMC SAN GABRIEL VALLEY MEDICAL
SAN GABRIEL, CA 91776
SAN GABRIEL, CA 91776
33aNPI1275720377assigned 10/02/2007
33bProvider typeGeneral Acute Care Hospital
28Total paid$6.96M
24GClaims364,508
24DCodes billed140
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in California
Rank by total paid#205 of 410
Median peer was paid$6.90M
This provider vs. median1.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official MARSH, LINDA controls 11+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 57,052 | $1.05M | |
| 2019 | 52,760 | $1.28M | |
| 2020 | 36,492 | $638K | |
| 2021 | 40,965 | $767K | |
| 2022 | 58,120 | $1.08M | |
| 2023 | 64,232 | $1.26M | |
| 2024incomplete | 54,887 | $894K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 0450 | Emergency room services | 21% | 43,425 | 39,963 | $1.49M |
| 70450 | Computed tomography, head or brain; without contrast material | 6.0% | 5,193 | 5,044 | $415K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 5.5% | 9,834 | 9,142 | $386K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 5.1% | 8,901 | 8,481 | $352K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.7% | 2,004 | 1,976 | $327K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 4.2% | 2,995 | 2,940 | $294K |
| J3490 | Unclassified drugs | 3.1% | 22,661 | 11,781 | $216K |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | 2.9% | 5,617 | 5,407 | $201K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 2.6% | 2,855 | 2,692 | $183K |
| 0270 | 2.5% | 16,832 | 9,137 | $177K | |
| 80053 | Comprehensive metabolic panel | 2.4% | 19,832 | 18,646 | $170K |
| 96375 | Therapeutic injection; each additional sequential IV push | 2.3% | 5,453 | 5,160 | $160K |
128 more codes
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 2.3% | 1,227 | $159K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.3% | 9,533 | $157K |
| 0360 | 2.2% | 2,218 | $155K | |
| 99199 | Unlisted special service, procedure or report | 2.0% | 5,944 | $142K |
| 99284 | Emergency room visit (serious) | 1.9% | 1,311 | $129K |
| 71045 | Radiologic examination, chest; single view | 1.8% | 13,769 | $126K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.6% | 5,648 | $113K |
| S3620 | Newborn metabolic screening panel, includes test kit, postage and the laboratory tests specified by the state for inclusion in this panel (e.g., galactose; hemoglobin, electrophoresis; hydroxyprogesterone, 17-d; phenylalanine (pku); and thyroxine, total) | 1.6% | 756 | $109K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.5% | 21,516 | $102K |
| Z7502 | 1.4% | 2,809 | $99K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.2% | 2,000 | $83K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,463 | $55K |
| 0250 | <1% | 7,788 | $54K | |
| 84484 | <1% | 7,942 | $48K | |
| 83690 | <1% | 7,744 | $47K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 5,383 | $46K |
| 85730 | <1% | 4,447 | $39K | |
| 83880 | <1% | 2,243 | $38K | |
| 0710 | <1% | 2,419 | $37K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 1,337 | $36K |
| 81001 | <1% | 13,245 | $36K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 798 | $35K |
| 81025 | <1% | 7,262 | $33K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 319 | $32K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 3,111 | $30K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 5,131 | $27K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 181 | $26K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 5,265 | $26K |
| 0301 | <1% | 241 | $24K | |
| 85610 | <1% | 6,273 | $23K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 4,884 | $23K |
| 87040 | <1% | 1,535 | $21K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,499 | $21K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 464 | $20K |
| 76801 | <1% | 476 | $19K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,951 | $19K |
| A4217 | Sterile water/saline, 500 ml | <1% | 2,087 | $17K |
| 0272 | <1% | 3,060 | $17K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 277 | $16K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,640 | $15K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,986 | $14K |
| 73610 | <1% | 720 | $14K | |
| Z9725 | <1% | 318 | $14K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,084 | $13K |
| 0636 | <1% | 152 | $13K | |
| 86900 | <1% | 1,954 | $12K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 312 | $11K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 287 | $11K |
| 83735 | <1% | 2,764 | $10K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 333 | $10K |
| 73630 | <1% | 606 | $10K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,950 | $10K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,987 | $9K |
| 84702 | <1% | 1,006 | $9K | |
| 90715 | <1% | 345 | $9K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 619 | $8K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,563 | $8K |
| 73130 | <1% | 394 | $8K | |
| J2704 | Injection, propofol, 10 mg | <1% | 1,434 | $7K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,164 | $7K |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,366 | $7K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,617 | $7K |
| 87186 | <1% | 1,255 | $7K | |
| 73562 | <1% | 437 | $6K | |
| 83605 | <1% | 1,078 | $6K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,020 | $5K |
| 86901 | <1% | 2,117 | $5K | |
| A4649 | Surgical supply; miscellaneous | <1% | 695 | $5K |
| 81003 | <1% | 2,769 | $5K | |
| 73030 | <1% | 251 | $5K | |
| 86850 | <1% | 1,186 | $5K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 338 | $4K |
| Z7610 | <1% | 284 | $4K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 2,688 | $4K |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 751 | $3K |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 831 | $3K |
| 85027 | <1% | 790 | $3K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 80 | $3K |
| 0324 | <1% | 120 | $3K | |
| 82948 | <1% | 1,112 | $2K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 16 | $2K |
| 84703 | <1% | 516 | $2K | |
| 73110 | <1% | 112 | $2K | |
| 93971 | <1% | 43 | $2K | |
| 99285 | Emergency room visit (most serious) | <1% | 18 | $2K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 422 | $2K |
| 99000 | <1% | 924 | $2K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 453 | $2K |
| 85007 | <1% | 788 | $2K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 167 | $1K |
| 72100 | <1% | 64 | $1K | |
| S0164 | Injection, pantoprazole sodium, 40 mg | <1% | 137 | $1K |
| 96376 | <1% | 191 | $1K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 28 | $1K |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | <1% | 181 | $1K |
| 87420 | <1% | 327 | $998.88 | |
| 74018 | <1% | 68 | $943.68 | |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 97 | $915.86 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 69 | $764.45 |
| 85380 | <1% | 247 | $636.69 | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 12 | $603.83 |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 13 | $603.22 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 16 | $541.47 |
| 0271 | <1% | 145 | $480.25 | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 15 | $477.15 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 56 | $460.04 |
| 76937 | <1% | 29 | $433.51 | |
| 87081 | <1% | 97 | $406.29 | |
| J1815 | Injection, insulin, per 5 units | <1% | 20 | $347.21 |
| 0459 | <1% | 21 | $317.36 | |
| 73080 | <1% | 26 | $311.79 | |
| 86141 | <1% | 45 | $245.79 | |
| 99070 | <1% | 49 | $218.90 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 56 | $216.29 |
| 84439 | <1% | 44 | $161.11 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 44 | $159.16 |
| 80061 | Lipid panel | <1% | 55 | $149.80 |
| 82550 | <1% | 41 | $144.22 | |
| 72040 | <1% | 12 | $144.21 | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 14 | $131.98 |
| 94760 | <1% | 122 | $117.02 | |
| 12001 | <1% | 12 | $84.00 | |
| 59025 | Fetal non-stress test | <1% | 13 | $79.69 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 30 | $65.68 |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 21 | $50.52 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 44 | $49.05 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 14 | $41.94 |
| 85651 | <1% | 13 | $5.70 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMARSH, LINDA (SENIOR VICE PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| Ahmc Garfield Medical Center LP | Monterey Park, CA | $17.83M |
| Ahmc Whittier Hospital Medical | Whittier, CA | $15.12M |
| Ahmc Anaheim Regional Medical | Anaheim, CA | $14.21M |
| Ahmc Monterey Park Hospital LP | Monterey Park, CA | $10.85M |
| Ahmc Greater El Monte Community | South El Monte, CA | $9.17M |
| Alhambra Hospital Medical Center, LP | Alhambra, CA | $6.90M |
| Ahmc Seton Medical Center LLC | Daly City, CA | $5.21M |
| Alhambra Hospital Medical Center, LP | Alhambra, CA | $1.57M |
| Ahmc San Gabriel Valley Medical | San Gabriel, CA | $249K |
| Alhambra Hospital Medical Center, LP | Alhambra, CA | $176K |
| Alhambra Hospital Medical Center, LP | Alhambra, CA | $34K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.